Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Advanced Haematological Malignancies

Next Previous
X
Search
Trial Profile

A Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses of the Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Advanced Haematological Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selinexor (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Karyopharm Therapeutics; NPM Pharma

    • Most Recent Events

    • 21 Mar 2020 Results of non-compartmental analyses conducted using pre-dose and post-dose plasma samples to characterize the PK of selinexor and KPT-375 (10-fold less active metabolite) were presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 04 Dec 2017 Results assessing the safety and efficacy of selinexor in patients with relapsed or refractory multiple myeloma and Waldenstrom's macroglobulinemia (n=81) published in the Blood
    • 31 Mar 2017 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top